Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Entrevista com José Antonio (Anonymus Gourmet) Gomes Pinheiro Machado,

View through CrossRef
Entrevista com o jornalista, advogado e apresentador de TV José Antonio (Anonymus Gourmet) Gomes Pinheiro Machado, por Adauto Locatelli Taufer e Daniela Favero Netto, em junho de 2024, para compor o Dossiê “História e memória do Colégio de Aplicação da UFRGS: 70 anos de ensino, de extensão e de pesquisa”.
Title: Entrevista com José Antonio (Anonymus Gourmet) Gomes Pinheiro Machado,
Description:
Entrevista com o jornalista, advogado e apresentador de TV José Antonio (Anonymus Gourmet) Gomes Pinheiro Machado, por Adauto Locatelli Taufer e Daniela Favero Netto, em junho de 2024, para compor o Dossiê “História e memória do Colégio de Aplicação da UFRGS: 70 anos de ensino, de extensão e de pesquisa”.

Related Results

Protecting stable biological nomenclatural systems enables universal communication: A collective international appeal
Protecting stable biological nomenclatural systems enables universal communication: A collective international appeal
Abstract The fundamental value of universal nomenclatural systems in biology is that they enable unambiguous scientific communication. However, the stability of thes...
Assessing the Prognostic Value of Serial Seattle Angina Questionnaire Scores in Chronic Coronary Disease
Assessing the Prognostic Value of Serial Seattle Angina Questionnaire Scores in Chronic Coronary Disease
BACKGROUND: Patient-centered prognostic assessment in chronic coronary disease is vital for treatment optimization. Although the Seattle Angina Questionnaire Su...
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
OBJECTIVE In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of...
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
Abstract The ODYSSEY OUTCOMES trial, comprising over 47 000 patient-years of placebo-controlled observation, demonstrated important reductions in the risk of recurre...
A románok nevei Anonymus gesztájában és ami körülöttük van (2. rész)
A románok nevei Anonymus gesztájában és ami körülöttük van (2. rész)
Az Anonymus (III. Béla király névtelen jegyzője) által használt három vlach név (plur. Blachii, Blasii, Blaci) a latin végződések eltávolításával valójában a Blach (nem Blachi), Bl...
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on...

Back to Top